Business · 17/11/20261 min read
Daewoong Pharmaceutical Presents Phase 1 Clinical Trial Data for New Autoimmune Disease Drug 'Plodicitinib' at ACR Convergence 2026
Summary
Presented at the American College of Rheumatology (ACR) conference… Confirmed over 90% BTK and ITK target coverage, securing early pharmacodynamic evidence Distinctive mechanism that simultaneously modulates T cells and B cells… Potential for development across a wide range of autoimmune...